---
title: "BUZZ-Wave Life rises after regaining full rights to genetic disorder therapy from GSK"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274547491.md"
datetime: "2026-02-02T17:48:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274547491.md)
  - [en](https://longbridge.com/en/news/274547491.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274547491.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/274547491.md) | [English](https://longbridge.com/en/news/274547491.md)


# BUZZ-Wave Life rises after regaining full rights to genetic disorder therapy from GSK

Shares of drug developer Wave Life Sciences (WVE.O) rise 3.6% to $13.40

Co says it has regained full rights to WVE-006, its experimental genetic disorder therapy, from GSK (GSK.L)

WVE plans to engage with the US FDA on a potential accelerated approval pathway, with regulatory feedback expected mid-2026 for the therapy

Co is testing the therapy as a potential treatment to alpha-1 antitrypsin deficiency, a genetic disorder that can lead to serious lung and liver diseases due to low levels of the protein alpha-1 antitrypsin

Data from its ongoing clinical trial testing WVE-006 is on track for Q1 of 2026, co says

“Decision is due to strategic re-prioritization by partner GSK vs. data driven as no new data were disclosed”- Jefferies

“We think it makes sense as GSK may be more interested in large indications, such as COPD”- Truist

WVE rose 37.4% last year

### 相關股票

- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [Wave Life Sciences (WVE.US)](https://longbridge.com/zh-HK/quote/WVE.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [Bioshares Biotech Clinical Trials Fd (BBC.US)](https://longbridge.com/zh-HK/quote/BBC.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)

## 相關資訊與研究

- [BUZZ-MiNK Therapeutics rises as it wins funding for child cancer cell therapy](https://longbridge.com/zh-HK/news/278530484.md)
- [BioMarin Pharmaceutical Highlights Growth Plan, VOXZOGO Milestones, and Amicus Deal at Conference](https://longbridge.com/zh-HK/news/279015256.md)
- [Altimmune Details Pemvidutide MASH Path: Breakthrough Therapy, FDA Feedback, Phase 3 Next Up](https://longbridge.com/zh-HK/news/278790627.md)
- [Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data](https://longbridge.com/zh-HK/news/278565911.md)
- [10:41 ETBota uruchamia SAION AI - platformę fizycznej sztucznej inteligencji dedykowaną bioprodukcji](https://longbridge.com/zh-HK/news/278742287.md)